2018年6月13日 · Objectives: In Japan, sodium-glucose co-transporter type 2 (SGLT2) inhibitors have been reported to be associated with serious skin and subcutaneous tissue disorders. A post-marketing surveillance (PMS) study suggested that the association was specific for ipragliflozin and, to a lesser extent for dapagliflozin.

Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) have revolutionized the treatment of type 2 diabetes mellitus during the last decade. It has not only proven to be very effective for glycemic control but also has adjunctive effects in the management of heart failure, hypertension, and diabetic nephropathy, and even contributes to weight loss.

Skin toxicity emerged as potential signal (e.g., rash, photosensitivity, urticaria as PTs), both for SGLT2-Is as a class and as individual drugs. Severe adverse skin events (81 reports, 7% of the skin cases) mainly occurred in females aged 18-65 using SGLT2-Is …

2021年11月7日 · Toxidermia, otherwise known as cutaneous adverse drug reactions (CADRs), are skin manifestations of drug administration. While most are mild, there can be a broad range in visual characteristics of the eruptions, presenting as a singular erythematous plaque on the trunk to a full body sloughing of skin.

2024年12月31日 · According to post-marketing surveillance of SGLT2 inhibitors, infections, pruritus, photosensitivity, and urticaria topped the reported list of 1136 cases of skin and subcutaneous tissue adverse drug reactions .

Hypersensitivity adverse events (AEs) have been reported in some patients with sodium-glucose cotransporter 2 (SGLT2) inhibitors, including a recent report of dermatological AEs in Japan.

2024年4月22日 · Comparing incidence rates of various inflammatory skin diseases among patients starting their type 2 diabetes treatment either on sodium-glucose cotransporter-2 (SGLT2) inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors, a population-based cohort study found a lower hazard for all skin conditions besides psoriasis in patients on SGLT2 ...

2024年12月22日 · Skin disorders occur more frequently with sodium-dependent glucose cotransporter type 2 (SGLT2) inhibitors than with other antidiabetic drugs. We conducted basic research using ipragliflozin, with the aim of identifying new measures to prevent skin disorders caused by SGLT2 inhibitors.

2018年6月13日 · Objectives: In Japan, sodium-glucose co-transporter type 2 (SGLT2) inhibitors have been reported to be associated with serious skin and subcutaneous tissue disorders. A post-marketing surveillance (PMS) study suggested that the association was specific for ipragliflozin and, to a lesser exten</span> …

2022年8月2日 · The most common symptoms are itching, redness and tears in the genital skin, making it uncomfortable to sit down, pass urine or have sexual intercourse. Urinary tract infections can cause